Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME).

Tobler LH, Bahrami SH, Kaidarova Z, Pitina L, Winkelman VK, Vanderpool SK, Guiltinan AM, Cooper S, Busch MP, Murphy EL.

Transfusion. 2010 Jul;50(7):1513-23. doi: 10.1111/j.1537-2995.2010.02634.x. Epub 2010 Mar 25.

2.

Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors.

Busch MP, Glynn SA, Stramer SL, Orland J, Murphy EL, Wright DJ, Kleinman S; NHLBI Retrovirus Epidemiology Donor Study (REDS) Group..

Transfusion. 2006 Mar;46(3):469-75.

PMID:
16533292
3.

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection.

Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW, et al.

N Engl J Med. 1996 Jun 27;334(26):1691-6.

4.

Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios.

El Ekiaby M, Moftah F, Goubran H, van Drimmelen H, LaPerche S, Kleinman S, Busch M, Lelie N.

Transfusion. 2015 Jun;55(6):1186-94. doi: 10.1111/trf.13061. Epub 2015 Mar 13.

PMID:
25766141
5.

Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.

Bruhn R, Lelie N, Busch M, Kleinman S; International NAT Study Group..

Transfusion. 2015 Jun;55(6):1195-205. doi: 10.1111/trf.13024. Epub 2015 Feb 27.

PMID:
25727549
6.

Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing.

Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP; National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group..

N Engl J Med. 2004 Aug 19;351(8):760-8.

7.

The natural history of hepatitis C virus infection: host, viral, and environmental factors.

Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D.

JAMA. 2000 Jul 26;284(4):450-6.

PMID:
10904508
8.

Hepatitis C virus prevalence and clearance among US blood donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index.

Murphy EL, Fang J, Tu Y, Cable R, Hillyer CD, Sacher R, Triulzi D, Gottschall JL, Busch MP; Retrovirus Epidemiology Donor Study..

J Infect Dis. 2010 Aug 15;202(4):576-84. doi: 10.1086/654882.

10.

[Discovery of a chronic HVC infection without seroconversion in a blood donor in France during 28 months].

Durand F, Danic B, Tardivel R, Semana G, Gouezec H, Martinot M, Marcellin P, Beauplet A.

Transfus Clin Biol. 2000 Jun;7(3):242-50. French.

PMID:
10919211
11.

Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors.

Elghouzzi MH, Bouchardeau F, Pillonel J, Boiret E, Tirtaine C, Barlet V, Moncharmont P, Maisonneuve P, du Puy-Montbrun MC, Lyon-Caen D, Couroucé AM.

Vox Sang. 2000;79(3):138-44.

PMID:
11111231
12.

Acute nosocomial HCV infection detected by NAT of a regular blood donor.

Larke B, Hu YW, Krajden M, Scalia V, Byrne SK, Boychuk LR, Klein J.

Transfusion. 2002 Jun;42(6):759-65.

PMID:
12147030
13.

Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.

Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, Le Roux M, Kuun E, Gulube S, Reddy R.

Transfusion. 2009 Jun;49(6):1115-25. doi: 10.1111/j.1537-2995.2009.02110.x. Epub 2009 Feb 27.

PMID:
19309474
14.

Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing.

Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Stramer SL.

Transfusion. 2010 Jul;50(7):1495-504. doi: 10.1111/j.1537-2995.2010.02622.x. Epub 2010 Mar 12.

PMID:
20345570
16.

Outcome of an optional HCV screening program for blood transfusion recipients in Ireland.

Davoren A, Dillon AD, Power JP, Donnellan J, Quinn JM, Willis JW, Lawlor EM, O'Riordan JM.

Transfusion. 2002 Nov;42(11):1501-6.

PMID:
12421225
17.

African americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data.

Mir HM, Stepanova M, Afendy M, Kugelmas M, Younossi ZM.

J Clin Gastroenterol. 2012 Sep;46(8):e62-5. doi: 10.1097/MCG.0b013e318238352b.

PMID:
22178959
19.
20.

Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays.

Galel SA, Strong DM, Tegtmeier GE, Holland PV, Kuramoto IK, Kemper M, Pietrelli L, Gallarda J.

Transfusion. 2002 Nov;42(11):1507-13.

PMID:
12421226

Supplemental Content

Support Center